Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexpramipexole Extension in ALS (ENVISION)
NCT01622088Phase 3Terminated
- Sponsor
- Knopp Biosciences
- Start
- Jun 2012
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of dexpramipexole in amyotrophic lateral sclerosis (ALS), sponsored by Knopp Biosciences. Primary endpoints: Number of Subjects Who Reported an Adverse Event at 32.2 weeks, Number of Subjects Who Experienced a Serious Adverse Event at 32.2 weeks and 5 more. Started Jun 2012; status: terminated.
02
Drugs
dexpramipexole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01622088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01622088.